HK Stock Movement | MIRXES-B (02629) Rises Nearly 8% in Early Trading, Partners with Walvax to Expand ASEAN Market and Build RNA Precision Medicine Innovation System

Stock News11-24

MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the signing of a memorandum of understanding with Walvax Biotechnology (300142.SZ) to deepen collaboration in molecular diagnostics and vaccine development, jointly expanding into the ASEAN and global markets. This partnership signifies a strategic synergy between a leader in precision diagnostics and a top-tier vaccine developer, laying a solid foundation for an RNA-centric preventive and precision medicine platform. Notably, in October, the company's flagship product, GASTROClear, received approval from China's National Medical Products Administration (NMPA), becoming the world's first and only molecular diagnostic IVD product approved for gastric cancer screening. A research report by Founder Securities highlighted that this milestone not only marks the company's "zero-to-one" commercialization breakthrough but also introduces a new valuation logic. The approval positions MIRXES-B to tap into China's vast gastric cancer screening market, serving as a key near-term performance catalyst.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128334973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128334973","market":"us","top_or_hot":-1,"title":"HK Stock Movement | MIRXES-B (02629) Rises Nearly 8% in Early Trading, Partners with Walvax to Expand ASEAN Market and Build RNA Precision Medicine Innovation System","media":"Stock News","content":"<p>MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the signing of a memorandum of understanding with Walvax Biotechnology (300142.SZ) to deepen collaboration in molecular diagnostics and vaccine development, jointly expanding into the ASEAN and global markets. This partnership signifies a strategic synergy between a leader in precision diagnostics and a top-tier vaccine developer, laying a solid foundation for an RNA-centric preventive and precision medicine platform. Notably, in October, the company's flagship product, GASTROClear, received approval from China's National Medical Products Administration (NMPA), becoming the world's first and only molecular diagnostic IVD product approved for gastric cancer screening. A research report by Founder Securities highlighted that this milestone not only marks the company's \"zero-to-one\" commercialization breakthrough but also introduces a new valuation logic. The approval positions MIRXES-B to tap into China's vast gastric cancer screening market, serving as a key near-term performance catalyst.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | MIRXES-B (02629) Rises Nearly 8% in Early Trading, Partners with Walvax to Expand ASEAN Market and Build RNA Precision Medicine Innovation System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | MIRXES-B (02629) Rises Nearly 8% in Early Trading, Partners with Walvax to Expand ASEAN Market and Build RNA Precision Medicine Innovation System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-24 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the signing of a memorandum of understanding with Walvax Biotechnology (300142.SZ) to deepen collaboration in molecular diagnostics and vaccine development, jointly expanding into the ASEAN and global markets. This partnership signifies a strategic synergy between a leader in precision diagnostics and a top-tier vaccine developer, laying a solid foundation for an RNA-centric preventive and precision medicine platform. Notably, in October, the company's flagship product, GASTROClear, received approval from China's National Medical Products Administration (NMPA), becoming the world's first and only molecular diagnostic IVD product approved for gastric cancer screening. A research report by Founder Securities highlighted that this milestone not only marks the company's \"zero-to-one\" commercialization breakthrough but also introduces a new valuation logic. The approval positions MIRXES-B to tap into China's vast gastric cancer screening market, serving as a key near-term performance catalyst.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1128334973","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128334973","pubTimestamp":1763949022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","RNA":"Avidity Biosciences, Inc.","BK4585":"ETF&股票定投概念","02629":"MIRXES-B","BK4505":"高瓴资本持仓","BK1161":"生物科技","BK4139":"生物科技","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"港股动向|MIRXES-B(02629)早盘涨近8%携手Walvax拓展东盟市场构建RNA精准医疗创新体系","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"02629":1},"content_text":"MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the signing of a memorandum of understanding with Walvax Biotechnology (300142.SZ) to deepen collaboration in molecular diagnostics and vaccine development, jointly expanding into the ASEAN and global markets. This partnership signifies a strategic synergy between a leader in precision diagnostics and a top-tier vaccine developer, laying a solid foundation for an RNA-centric preventive and precision medicine platform. Notably, in October, the company's flagship product, GASTROClear, received approval from China's National Medical Products Administration (NMPA), becoming the world's first and only molecular diagnostic IVD product approved for gastric cancer screening. A research report by Founder Securities highlighted that this milestone not only marks the company's \"zero-to-one\" commercialization breakthrough but also introduces a new valuation logic. The approval positions MIRXES-B to tap into China's vast gastric cancer screening market, serving as a key near-term performance catalyst.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128334973","isCrawlerRequest":true}